1. Home
  2. PTY vs BEAM Comparison

PTY vs BEAM Comparison

Compare PTY & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pimco Corporate & Income Opportunity Fund

PTY

Pimco Corporate & Income Opportunity Fund

N/A

Current Price

$12.18

Market Cap

2.5B

Sector

Finance

ML Signal

N/A

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

HOLD

Current Price

$24.42

Market Cap

2.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PTY
BEAM
Founded
N/A
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.7B
IPO Year
2002
2019

Fundamental Metrics

Financial Performance
Metric
PTY
BEAM
Price
$12.18
$24.42
Analyst Decision
Strong Buy
Analyst Count
0
14
Target Price
N/A
$52.21
AVG Volume (30 Days)
1.4M
1.8M
Earning Date
01-01-0001
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
82.31
EPS
N/A
N/A
Revenue
N/A
$24,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$39.64
P/E Ratio
N/A
N/A
Revenue Growth
N/A
33.33
52 Week Low
$11.58
$13.53
52 Week High
$14.69
$36.44

Technical Indicators

Market Signals
Indicator
PTY
BEAM
Relative Strength Index (RSI) N/A 46.20
Support Level N/A $23.42
Resistance Level N/A $25.69
Average True Range (ATR) 0.00 1.32
MACD 0.00 0.04
Stochastic Oscillator 0.00 59.52

Price Performance

Historical Comparison
PTY
BEAM

About PTY Pimco Corporate & Income Opportunity Fund

PIMCO Corporate & Income Opportunity Fds operates as a closed-end management investment company. It seeks to maximize total return through a combination of current income and capital appreciation. The fund invests a majority of the total assets in a combination of corporate debt obligations of varying maturities, other corporate income-producing securities, and income-producing securities of non-corporate issuers, such as U.S. Government securities, municipal securities, and mortgage-backed and other asset-backed securities issued on a public or private basis.

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

Share on Social Networks: